MSMB and prostate cancer: Previous exposure to antiandrogenic drugs did not affect the ratio of MSMB or HNF1B splice variants in samples from prostate cancer or BPH patients (P = 0.24 in untreated subjects and 0.69 in treated subjects for prostate cancer cohort and P = 0.88 24 in untreated subjects and 0.72 in treated subjects for the BPH cohort).